Developing advanced genetic tools to study cancer in personalized tumor models
Enabling in vivo barcoded single-cell multiomics-compatible genome-wide screens in personalized tumor models using defined-copy somatic transgenesis
This study is exploring a new way to use CRISPR technology to learn more about how genes affect cancer, which could help create better, personalized treatments for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11031374 on NIH RePORTER |
What this research studies
This research focuses on enhancing CRISPR technology to better understand the genetic mechanisms behind cancer. By using a novel method called MADR Perturb-seq, the team aims to conduct large-scale genetic screens in living models, which could lead to more effective cancer treatments. The approach involves non-invasive techniques to introduce genetic changes and analyze their effects on tumor development. Patients may benefit from insights gained through this research that could lead to personalized therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research include pediatric and adult patients with various types of cancer, particularly those who may benefit from advanced genetic analysis.
Not a fit: Patients with non-cancerous conditions or those who do not have access to the required genetic testing may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to breakthroughs in personalized cancer treatments tailored to individual genetic profiles.
How similar studies have performed: Previous research has shown promising results using CRISPR technology for cancer studies, indicating a strong potential for success with this novel approach.
Where this research is happening
Los Angeles, United States
- Cedars-Sinai Medical Center — Los Angeles, United States (Active)
Researchers
- Principal investigator: Breunig, Joshua John — Cedars-Sinai Medical Center
- Study coordinator: Breunig, Joshua John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.